Journal of Cancer Research and Therapeutics Close
 

Figure 1: A 55-year-old man who underwent baseline and postneoadjuvant PET/CT for a pathologically proven esophageal adenocarcinoma cancer with T3N1M0 (stage III) disease. At baseline PET/CT, an intense FDG-uptake was showed at distal thoracic esophagus with a SUVmax of 7.35 and a TLG of 559.82. The patient underwent combined neoadjuvant therapy (taxotere + cisplatin + fl uorouracil and radiotherapy). PET/CT after treatment showed a less intense uptake of FDG in the same site with a SUVmax of 2 and a TLG of 56. Therefore, the change in SUVmax was 52% and in TLG was 90%. After 2 weeks from the second PET/CT, the patient was treated with a defi nitive surgery demonstrating a fi nal stage I (partial response to combined neo-adjuvant therapy). After 17 months from the second PET/CT, the patient was alive without evidence of disease

Figure 1: A 55-year-old man who underwent baseline and postneoadjuvant PET/CT for a pathologically proven esophageal adenocarcinoma cancer with T3N1M0 (stage III) disease. At baseline PET/CT, an intense FDG-uptake was showed at distal thoracic esophagus with a SUVmax of 7.35 and a TLG of 559.82. The patient underwent combined neoadjuvant therapy (taxotere + cisplatin + fl uorouracil and radiotherapy). PET/CT after treatment showed a less intense uptake of FDG in the same site with a SUVmax of 2 and a TLG of 56. Therefore, the change in SUVmax was 52% and in TLG was 90%. After 2 weeks from the second PET/CT, the patient was treated with a defi nitive surgery demonstrating a fi nal stage I (partial response to combined neo-adjuvant therapy). After 17 months from the second PET/CT, the patient was alive without evidence of disease